# 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

> **NCT05139004** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 7 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Secondary Acute Myeloid Leukemia

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **BIOLOGICAL:** Basiliximab
- **DRUG:** Fludarabine Phosphate
- **DRUG:** Indium In 111-DOTA-Basiliximab
- **DRUG:** Melphalan
- **BIOLOGICAL:** Palifermin
- **RADIATION:** Total Lymphoid Irradiation
- **RADIATION:** Total Marrow Irradiation
- **BIOLOGICAL:** Yttrium Y 90 Basiliximab

## Key facts

- **NCT ID:** NCT05139004
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-19
- **Primary completion:** 2027-06-13
- **Final completion:** 2027-06-13
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05139004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05139004, "90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05139004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*